NASDAQ:CORI Corium International (CORI) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free CORI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.68▼$12.6850-Day Range N/A52-Week Range$7.17▼$13.93VolumeN/AAverage Volume577,723 shsMarket Capitalization$459.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Corium International alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Corium International Stock (NASDAQ:CORI)Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.Read More Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide CORI Stock News HeadlinesJanuary 22, 2024 | ca.finance.yahoo.comQUEBEC AI INNOVATION: COGINOV AND CORIUM JOIN FORCES FOR ACCELERATED GROWTHAugust 10, 2023 | businesswire.comCorium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across AsiaApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.July 6, 2023 | investopedia.comBest International Student LoansMay 23, 2023 | travel.usnews.comThe 5 Best International Travel Insurance Companies for 2023May 15, 2023 | marketwatch.comGlobal 2023, Passive Transdermal Drug Delivery Market Analysis of New Report 2030April 28, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share by 2031April 21, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Research, 2023-2030April 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 30, 2023 | marketwatch.com2023 Passive Transdermal Drug Delivery Market Size, Growth | Global Industry Trends [2029]March 30, 2023 | marketwatch.comVaccine Delivery Devices Market Share and Forecast till 2031March 28, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share Likely to Grow At a Impressive CAGRMarch 18, 2023 | marketwatch.comMicroneedle Flu Vaccine Market: Forecast for 2023-2028 with Emerging TechnologiesMarch 15, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market | Global Various Tendencies Industry Report, 2029March 13, 2023 | marketwatch.comVaccines Delivery Devices Market Share, Trends, Growth, Size and Segmentation by 2023 to 2028March 11, 2023 | marketwatch.com2023-2028 Vaccines Delivery Devices Market Size Report: Global Growth Drivers and Market Share AnalysisMarch 6, 2023 | msn.comHow a hobby turned into a successful business for Corium Skincare's Vuyi ZondiMarch 1, 2023 | finance.yahoo.comCorium Pharma Solutions Names Suzanne Hinchliffe as Chief People OfficerFebruary 23, 2023 | marketwatch.comVaccine Delivery Devices Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028February 22, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market is Booming in Near Future 2023-2028February 10, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market 2023 Structure Along With Size, Trends, Revenue, Market segments, Forecast to 2029February 8, 2023 | benzinga.comGlobal Alzheimer's Disease Therapeutics Market Research Report 2023: Forecasts, Epidemiology & Pipeline Analysis 2022-2028December 8, 2022 | marketwatch.comPassive Transdermal Drug Delivery Market : Research Report Provides an In-Depth Insight of Trends 2022 To 2028November 10, 2022 | msn.comBiogen picks Christopher Viehbacher, former leader of Sanofi, as new CEOAugust 23, 2022 | marketwatch.comClonidine Market Size and Share 2022 Analysis Report by Key Players, Geographical Regions, Future Development and Forecast to 2028August 20, 2022 | msn.comTrial results show promise for new Alzheimer’s skin patchAugust 3, 2022 | yahoo.comGluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD DrugsSee More Headlines Receive CORI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corium International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORI CUSIPN/A CIK1594337 Webwww.coriumgroup.com Phone650-298-8255FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,790,000.00 Net Margins-155.21% Pretax MarginN/A Return on Equity-276.89% Return on Assets-57.52% Debt Debt-to-Equity Ratio2.83 Current Ratio7.61 Quick Ratio7.47 Sales & Book Value Annual Sales$31.86 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book28.18Miscellaneous Outstanding Shares36,250,000Free FloatN/AMarket Cap$459.65 million OptionableOptionable Beta0.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Peter D. Staple (Age 66)Pres, CEO & Director Mr. Robert S. Breuil (Age 56)Chief Financial Officer Dr. Parminder Singh (Age 54)CTO & VP of R&D Mr. Timothy D. Sweemer CPAChief Accounting Officer, VP of Admin. & Sec.Ms. Christina DickersonVP of Corp. Devel.Key CompetitorsFulcrum TherapeuticsNASDAQ:FULCAnnexonNASDAQ:ANNXAvid BioservicesNASDAQ:CDMOLarimar TherapeuticsNASDAQ:LRMRMersana TherapeuticsNASDAQ:MRSNView All Competitors CORI Stock Analysis - Frequently Asked Questions How were Corium International's earnings last quarter? Corium International, Inc. (NASDAQ:CORI) issued its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative net margin of 155.21% and a negative trailing twelve-month return on equity of 276.89%. What other stocks do shareholders of Corium International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corium International investors own include Intelsat (I), Iovance Biotherapeutics (IOVA), Aralez Pharmaceuticals (ARLZ), Cypress Semiconductor (CY), Energy Transfer (ET), Exelixis (EXEL), AMC Entertainment (AMC), Global Blood Therapeutics (GBT), SunCoke Energy Partners (SXCP) and Zynga (ZNGA). This page (NASDAQ:CORI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corium International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
